Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Alkermes, Inc.
Scientific Title
A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1